SCHEMBL19690907

SCHEMBL19690907

FCc1ccn(-c2nc(Nc3ccc(Cl)cc3)cc(N3CCOCC3)n2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
S1PR2 O95136 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PIK3CD O00329 3/20 0.41
PIK3CB P42338 3/20 0.41
PIK3CA P42336 2/20 0.41
AKT1 P31749 1/20 0.41
PIK3CG P48736 1/20 0.41
THRB P10828 1/20 0.41
SMG1 Q96Q15 1/20 0.41
GBA1 P04062 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19690995 0.91 MAPT (0.46) LMNAMAPTKDM4EHPGDPIK3CD
SCHEMBL19690972 0.91 GBA1 (0.45) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19690997 0.85 MAPT (0.44) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19708879 0.83 MAPT (0.44) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19691008 0.83 MAPT (0.46) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL19708703 0.83 MAPT (0.43) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19690957 0.82 MAPT (0.45) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19708726 0.81 MAPT (0.43) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19708722 0.81 MAPT (0.43) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL19708723 0.81 ADORA2A (0.47) LMNAMAPTKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 LMNA 1523/4885MAPT 1877/4885KDM4E 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.